H

Hansoh Pharmaceutical Group Company Ltd
HKEX:3692

Watchlist Manager
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Watchlist
Price: 18.52 HKD 1.42% Market Closed
Market Cap: 109.9B HKD
Have any thoughts about
Hansoh Pharmaceutical Group Company Ltd?
Write Note

Hansoh Pharmaceutical Group Company Ltd
Short-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Hansoh Pharmaceutical Group Company Ltd
Short-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Short-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Short-Term Debt
ÂĄ0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Short-Term Debt
ÂĄ1.1B
CAGR 3-Years
15%
CAGR 5-Years
6%
CAGR 10-Years
57%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Short-Term Debt
ÂĄ249m
CAGR 3-Years
-19%
CAGR 5-Years
N/A
CAGR 10-Years
37%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Short-Term Debt
ÂĄ4.1B
CAGR 3-Years
20%
CAGR 5-Years
20%
CAGR 10-Years
21%
C
CSPC Innovation Pharmaceutical Co Ltd
SZSE:300765
Short-Term Debt
ÂĄ73.5m
CAGR 3-Years
N/A
CAGR 5-Years
36%
CAGR 10-Years
N/A
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Short-Term Debt
ÂĄ318.9m
CAGR 3-Years
23%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Hansoh Pharmaceutical Group Company Ltd
Glance View

Market Cap
109.9B HKD
Industry
Pharmaceuticals

Hansoh Pharmaceutical Group Company Ltd., founded in 1995 and headquartered in Jiangsu, China, has rapidly evolved into one of the leading biopharmaceutical enterprises in the country. With a robust portfolio that spans biologics, small molecule drugs, and innovative therapies, Hansoh has carved a niche for itself by focusing on high-demand therapeutic areas such as oncology, central nervous system disorders, and autoimmune diseases. The company thrives on its commitment to research and development, partnering with academic institutions and international firms to drive innovation, which is pivotal in a competitive industry characterized by rapid technological advancements. Investors will find comfort in Hansoh's strong growth trajectory, marked by impressive revenue increases and a strategic intent to expand its footprint both domestically and globally. As the Chinese healthcare market continues to burgeon, driven by an aging population and evolving consumer demands, Hansoh Pharmaceutical is well-positioned to capitalize on these trends. Its recent listings on major global stock exchanges signal its ambition to attract international investors and strengthen its balance sheet for future endeavors. The company's strategic initiatives aim to diversify its product offerings and improve access to its innovative drugs, setting it apart from its competitors. With a management team that emphasizes prudent decision-making and value creation—echoing the principles of investment legends like Warren Buffett and Charlie Munger—Hansoh is not just a company; it is a growing story of success in the burgeoning pharmaceutical landscape that promises to deliver sustained value for its shareholders in the years to come.

Intrinsic Value
15.76 HKD
Overvaluation 15%
Intrinsic Value
Price
H

See Also

What is Hansoh Pharmaceutical Group Company Ltd's Short-Term Debt?
Short-Term Debt
0 CNY

Based on the financial report for Dec 31, 2023, Hansoh Pharmaceutical Group Company Ltd's Short-Term Debt amounts to 0 CNY.

Back to Top